Rinvoq (upadacitinib, AbbVie) and Humira (adalimumab, AbbVie) are two of the most important therapies in immune-mediated disease -- and they represent fundamentally different approaches. Rinvoq is an oral, preferential JAK1 inhibitor. Humira is an injectable TNF-alpha monoclonal antibody. Both are made by the same company, both treat overlapping disease states, and both face access barriers that are reshaping how prescribers and payers approach treatment sequencing.
The access landscape has shifted dramatically. All three major PBMs have excluded brand Humira from their 2026 formularies in favor of adalimumab biosimilars that cost 81-87% less. Rinvoq, meanwhile, carries a class-wide boxed warning that restricts its use to patients who have already failed a TNF blocker in most indications. The result: payers increasingly want patients to try a low-cost adalimumab biosimilar before Rinvoq, creating a formulary pathway that neither drug's label was designed to anticipate.
This comparison is for access teams, prior authorization coordinators, and prescribers who need to understand how these two products compare on label, safety, cost, and coverage -- and what those differences mean for the patient in front of them.
Short answer
| Rinvoq (upadacitinib) | Humira (adalimumab) | |
|---|---|---|
| Drug class | JAK inhibitor (preferential JAK1 selectivity) | TNF inhibitor (monoclonal antibody) |
| Manufacturer | AbbVie | AbbVie (brand); 10 biosimilar manufacturers |
| Route | Oral tablet (15 mg, 30 mg, 45 mg ER once daily); oral solution (Rinvoq LQ) | Subcutaneous injection (40 mg every other week); autoinjector and prefilled syringe |
| FDA indications | 9 indications (RA, PsA, pJIA, AS, nr-axSpA, UC, CD, AD, GCA) | 9 indications (RA, JIA, PsA, AS, plaque psoriasis, CD, UC, hidradenitis suppurativa, uveitis) |
| Boxed warning | Yes (infections, mortality, malignancy, MACE, thrombosis) | No |
| First-line use? | No -- TNF blocker failure required for most indications (except GCA) | Yes (no prior therapy required on label) |
| Biosimilar competition | None (small molecule, no biosimilar pathway) | Yes -- 10 FDA-approved biosimilars, 8 interchangeable |
| Brand WAC | ~$6,700-$7,200/month | ~$6,923/carton (brand); biosimilars from $899-$6,576 |
| 2026 formulary status (major PBMs) | Preferred or Tier 2 with PA | Brand excluded; biosimilars preferred |
| PA required | Yes, universally | Yes for brand (when available); varies for biosimilars |
Mechanism and clinical differentiation
Rinvoq and Humira target the immune system through entirely different pathways.
Rinvoq (upadacitinib) is a small-molecule, preferential JAK1 inhibitor taken orally. The JAK-STAT signaling pathway is central to the inflammatory cascade in multiple immune-mediated diseases. By preferentially inhibiting JAK1, Rinvoq blocks signaling for cytokines including IL-6, IL-4, IL-2, IFN-gamma, and others involved in RA, PsA, IBD, and atopic dermatitis. Oral administration is a practical advantage for patients who are needle-averse or who have difficulty accessing injection supplies.
Humira (adalimumab) is a fully human monoclonal antibody administered by subcutaneous injection. It binds specifically to TNF-alpha, a pro-inflammatory cytokine central to the pathogenesis of RA, PsA, CD, UC, and other conditions. TNF inhibition has been the dominant biologic strategy in rheumatology and gastroenterology for over two decades.
The key clinical distinction for access: Rinvoq's mechanism comes with a class-wide boxed warning based on the ORAL Surveillance trial (conducted with tofacitinib, another JAK inhibitor), which demonstrated increased risks of serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality. Humira has no boxed warning, which gives it a label advantage in treatment sequencing -- even though TNF inhibitors also carry serious infection and malignancy warnings in their prescribing information.
FDA-approved indications comparison
| Indication | Rinvoq | Humira |
|---|---|---|
| Rheumatoid arthritis (adults, moderate-to-severe) | Yes (after TNF blocker failure) | Yes (first-line) |
| Psoriatic arthritis (adults) | Yes (after TNF blocker failure) | Yes (first-line) |
| Juvenile idiopathic arthritis / polyarticular JIA | Yes (pJIA, age 2+, after TNF blocker failure) | Yes (JIA, age 2+) |
| Ankylosing spondylitis (adults) | Yes (after TNF blocker failure) | Yes (first-line) |
| Non-radiographic axial spondyloarthritis | Yes (after TNF blocker failure) | Not approved |
| Ulcerative colitis (adults, moderate-to-severe) | Yes (after TNF blocker failure or if TNF blockers clinically inadvisable, after at least 1 approved systemic therapy) | Yes (first-line) |
| Crohn's disease (adults, moderate-to-severe) | Yes (after TNF blocker failure or if TNF blockers clinically inadvisable, after at least 1 approved systemic therapy) | Yes (first-line) |
| Atopic dermatitis | Yes (age 12+, refractory, after failure of other systemic therapies including biologics) | Not approved |
| Giant cell arteritis (adults) | Yes (after glucocorticoid failure; no TNF blocker prerequisite) | Not approved |
| Plaque psoriasis (adults, moderate-to-severe) | Not approved | Yes (first-line) |
| Hidradenitis suppurativa (adults) | Not approved | Yes (first-line) |
| Uveitis (adults) | Not approved | Yes (first-line) |
Key differences in label positioning:
- Rinvoq requires prior TNF blocker failure for 8 of 9 indications. The only exception is giant cell arteritis, which requires only a glucocorticoid trial. This is a label restriction, not just a payer preference -- it reflects the FDA's determination that the boxed warning risks are not justified for first-line use in most populations.
- Humira carries no prior therapy requirement. It is labeled for first-line use in all nine of its indications. This makes Humira (and its biosimilars) the logical starting point in treatment algorithms.
- Each drug has unique indications the other lacks. Rinvoq is approved for atopic dermatitis, non-radiographic axial spondyloarthritis, and giant cell arteritis. Humira is approved for plaque psoriasis, hidradenitis suppurativa, and uveitis. These unique indications cannot be interchanged.
- Rinvoq cannot be combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants. This limits concomitant therapy options.
SELECT-SWITCH head-to-head trial data
AbbVie's SELECT-SWITCH Phase 3b/4 trial provides the only direct head-to-head efficacy comparison between Rinvoq and Humira. Results were reported in October 2025.
| Parameter | Result |
|---|---|
| Study design | Phase 3b/4, head-to-head, RA patients who had failed prior TNF inhibitor |
| Rinvoq arm | Upadacitinib 15 mg once daily (oral) |
| Humira arm | Adalimumab 40 mg every other week (SC injection) |
| Primary endpoint | Disease Activity Score (DAS28-CRP) remission or low disease activity at 12 weeks |
| Rinvoq response rate | 43% achieved symptom relief |
| Humira response rate | 22% achieved symptom relief |
| Statistical significance | Rinvoq superior to adalimumab |
| Population | RA patients who had already failed at least one TNF inhibitor |
The SELECT-SWITCH data suggest that in TNF-inadequate responder (TNF-IR) patients with RA, Rinvoq may offer superior efficacy compared to switching to another TNF inhibitor. This is clinically relevant because it supports the treatment sequence implied by Rinvoq's label: TNF blocker first, then Rinvoq.
However, the trial does not address the first-line comparison. Because Rinvoq is not labeled for first-line use in RA (due to the boxed warning), SELECT-SWITCH data cannot be used to support Rinvoq before a TNF blocker trial, regardless of the efficacy signal.
Boxed warning and safety profiles
Rinvoq boxed warning
The FDA requires a boxed warning on all JAK inhibitors, including Rinvoq, based on data from the ORAL Surveillance trial (tofacitinib). The warning covers:
- Serious infections: Tuberculosis, invasive fungal infections, bacterial, viral, and opportunistic infections, some fatal
- Mortality: Increased all-cause mortality
- Malignancy: Including lymphoma and non-melanoma skin cancer
- Major adverse cardiovascular events (MACE): Myocardial infarction and stroke
- Thrombosis: Deep venous thrombosis, pulmonary embolism, arterial thrombism
This boxed warning applies to all JAK inhibitors regardless of individual drug selectivity. It is the primary reason Rinvoq is labeled for use after TNF blocker failure in most indications.
Humira safety profile
Humira carries serious warnings but no boxed warning:
- Serious infections: Including tuberculosis, invasive fungal infections, and other opportunistic pathogens; some fatal
- Malignancies: Including lymphoma (rare cases of hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease)
- Heart failure: Worsening and new-onset heart failure
- Hematologic reactions: Cytopenias, including pancytopenia
- Neurologic reactions: Demyelinating disease, including multiple sclerosis, Guillain-Barre syndrome
- Autoimmune reactions: Lupus-like syndrome
- Hepatitis B reactivation
Practical implications
| Safety factor | Rinvoq | Humira |
|---|---|---|
| Boxed warning | Yes | No |
| Prior therapy required (label) | TNF blocker failure (most indications) | None |
| TB screening | Required before initiation | Required before initiation |
| CV risk screening | Recommended (boxed warning) | Standard monitoring |
| Combination restrictions | No other JAK inhibitors, biologic DMARDs, or potent immunosuppressants | No other TNF inhibitors; combine with MTX common |
| Monitoring frequency | CBC, lipids, LFTs at baseline and periodically | LFTs, CBC at baseline and periodically |
The boxed warning asymmetry is the single most important factor shaping access. Payers and the FDA both treat Humira (and adalimumab biosimilars) as lower-risk first-line options. Rinvoq is positioned as a second-line or later therapy.
Humira biosimilar landscape
Humira lost US exclusivity on January 31, 2023. Ten FDA-approved biosimilars are now marketed:
| Biosimilar | Manufacturer | Interchangeable | WAC (per carton) | Pricing tier |
|---|---|---|---|---|
| Amjevita (adalimumab-atto) | Amgen | Yes | High-list and low-list versions available | Both tiers |
| Cyltezo (adalimumab-adbm) | Boehringer Ingelheim | Yes | ~$6,576 (high-list) | High-list |
| Hyrimoz (adalimumab-adaz) | Sandoz | Yes | ~$6,576 (high-list) | High-list |
| Hadlima (adalimumab-bwwd) | Samsung Bioepis/Organon | Yes | ~$1,038 | Low-list |
| Abrilada (adalimumab-afzb) | Pfizer | Yes | High-list and low-list versions | Both tiers |
| Hulio (adalimumab-fkjp) | Mylan/Viatris | Yes | ~$995 | Low-list |
| Yusimry (adalimumab-aqvh) | Coherus | No | ~$995 | Low-list |
| Idacio (adalimumab-aacf) | Fresenius Kabi | No | ~$899 (unbranded) | Low-list |
| Yuflyma (adalimumab-aaty) | Celltrion | Yes | ~$995 | Low-list |
| Simlandi (adalimumab-ryvk) | Teva/Alvotech | Yes | ~$1,038 | Low-list |
Eight of ten biosimilars carry interchangeability designations, meaning pharmacists can substitute them for brand Humira at the point of dispensing without contacting the prescriber (subject to state law).
Despite biosimilar availability, brand Humira still accounted for over 98% of adalimumab prescriptions even after biosimilar entry, driven by rebate-driven formulary positioning. This dynamic shifted dramatically in 2024-2026 as PBMs moved to exclude brand Humira.
Coverage comparison by payer
Commercial insurance
| PBM/Payer | Rinvoq | Humira (brand) | Adalimumab biosimilars |
|---|---|---|---|
| Express Scripts 2026 NPF | Preferred | Excluded | Preferred: adalimumab-adaz, adalimumab-adbm (BI and Quallent), adalimumab-ryvk (Quallent), Simlandi |
| CVS Caremark 2026 | Covered with PA | Excluded since April 2024 | Preferred: Cordavis/Sandoz products, Biocon |
| Optum Rx 2026 | Tier 2 with PA, specialty, quantity limits | Excluded from Premium/Select | Preferred: Amjevita (high-list Amgen, low-list Nuvaila) |
| Cigna | PA required; TNF blocker failure; specialist required | Covered but non-preferred | Biosimilars preferred where available |
| UnitedHealthcare | PA required; TNF blocker failure for most indications | Covered but non-preferred | Biosimilars generally preferred |
The common pattern across all major PBMs in 2026:
- Brand Humira is excluded. Patients on Humira are being transitioned to biosimilar adalimumab products.
- Rinvoq requires PA with TNF blocker failure documentation. This aligns with the FDA label and the boxed warning.
- Low-list-price adalimumab biosimilars are preferred. Products priced at $899-$1,038/carton are winning formulary positioning.
- The treatment sequence is effectively: adalimumab biosimilar first, then Rinvoq. This creates a payer-mandated pathway where patients try a TNF inhibitor (cheap biosimilar) before accessing Rinvoq, which mirrors Rinvoq's own label requirements.
Medicare Part D
| Factor | Rinvoq | Humira (brand) | Adalimumab biosimilars |
|---|---|---|---|
| Formulary status | Covered; specialty tier | Declining; many plans excluding brand | Preferred on most plans |
| 2026 OOP cap | $2,100/year (IRA) | $2,100/year (IRA) | $2,100/year (IRA) |
| LIS copay (2026) | $12.65 or less per fill | $12.65 or less per fill | $12.65 or less per fill |
| Extra Help/LIS utilization | 65% of Rinvoq rheumatology Medicare patients use Extra Help/LIS | N/A | Varies |
| PA required | Yes | Yes for brand | Generally no for biosimilars |
Medicare Part D beneficiaries pay significantly less in 2026 due to the IRA's $2,100 annual out-of-pocket cap. For Rinvoq, the majority of rheumatology patients on Medicare qualify for Extra Help (LIS), which caps copays at $12.65 per fill in 2026.
For adalimumab products, the availability of low-list-price biosimilars means that Medicare beneficiaries who are switched from brand Humira to a biosimilar may see lower costs even before the OOP cap applies.
Medicaid
| Factor | Rinvoq | Adalimumab (brand or biosimilar) |
|---|---|---|
| Coverage | Covered with PA | Covered; biosimilars increasingly preferred |
| PA criteria | TNF blocker failure, diagnosis confirmation, specialist prescriber | Varies; less stringent than Rinvoq |
| Copay | $0-$8/month depending on state | $0-$8/month depending on state |
| Step therapy | TNF inhibitor required (label-concordant) | First-line; no prior therapy required |
State Medicaid programs generally align with Rinvoq's label requirements, requiring documented TNF blocker failure before approving Rinvoq. Biosimilar adalimumab products are increasingly preferred for the TNF inhibitor step.
Prior authorization comparison
Rinvoq PA requirements
| PA criterion | Details |
|---|---|
| Diagnosis documentation | Disease activity scores, imaging, endoscopy (for IBD), or other objective measures |
| Prior TNF blocker failure | Drug name, dose, duration (typically 3+ months at adequate dose), and reason for discontinuation |
| Contraindications to other therapies | Documentation of intolerance, contraindication, or inadequate response |
| Specialist prescriber | Rheumatologist (RA, PsA, AS, nr-axSpA, pJIA, GCA), gastroenterologist (CD, UC), or dermatologist (AD) |
| Safety screening | TB test, hepatitis B screen, CBC, lipids, LFTs |
| Exclusion of combination therapy | No concurrent JAK inhibitors, biologic DMARDs, or potent immunosuppressants |
| Payer-specific: Cigna | Requires TNF blocker failure AND prescribed by or in consultation with specialist |
| Payer-specific: UnitedHealthcare | TNF blocker failure required for most indications; quantity limits apply |
| Payer-specific: Optum Rx | Tier 2 with PA; specialty designation; quantity limits |
Humira / adalimumab biosimilar PA requirements
| PA criterion | Details |
|---|---|
| Diagnosis documentation | Diagnosis-specific (RA, CD, UC, PsA, etc.) |
| Prior therapy | Generally no prior therapy required for first-line indications |
| Step therapy | Some plans may require trial of preferred biosimilar before non-preferred biosimilar |
| Brand Humira | PA required and likely denied (non-formulary on all three major PBMs) |
| Biosimilars | Most preferred biosimilars do not require PA on commercial plans |
| Interchangeable biosimilars | Can be dispensed at pharmacy level without prescriber contact in most states |
The PA burden is substantially higher for Rinvoq than for preferred adalimumab biosimilars. This difference in administrative complexity is a practical access barrier that affects prescribing behavior.
Cost comparison
| Cost metric | Rinvoq | Humira (brand) | Low-list adalimumab biosimilars |
|---|---|---|---|
| WAC (monthly) | ~$6,700-$7,200 | ~$6,923/carton | $899-$1,038/carton |
| WAC discount vs brand Humira | N/A (different molecule) | Reference | 81-87% below Humira WAC |
| Commercial copay with savings card | As low as $0/fill (Rinvoq Complete) | Available but product is non-formulary | Varies; generally lower copay than brand |
| Medicare Part D (2026) | $0-$2,100/year | $0-$2,100/year | $0-$2,100/year |
| Medicare LIS copay (2026) | $12.65 or less/fill | $12.65 or less/fill | $12.65 or less/fill |
| Medicaid | $0-$8/month | $0-$8/month | $0-$8/month |
| Uninsured (WAC) | ~$6,700-$7,200/month | ~$6,923/carton | $899-$1,038/carton |
The cost asymmetry is significant. A low-list adalimumab biosimilar at $899-$1,038 per carton is roughly one-seventh the price of Rinvoq. Even with Rinvoq's savings card bringing commercial copays to $0, the plan is still paying the full WAC -- and that cost eventually flows through to premiums and formulary design decisions.
This is why payers prefer the adalimumab biosimilar-first pathway. It is both clinically appropriate (Humira has no boxed warning and is labeled first-line) and economically advantageous (biosimilar adalimumab costs a fraction of Rinvoq).
Savings and assistance programs
Rinvoq programs
| Program | Eligibility | Benefit |
|---|---|---|
| Rinvoq Complete Savings Card | Commercially insured patients | As low as $0 per fill; maximum annual benefit applies |
| Rinvoq Bridge Program | Commercially insured with PA denial and confirmed appeal | Free Rinvoq for up to 2 years or until insurance approval |
| myAbbVie Assist | Uninsured or underinsured who cannot afford medication | Free medication for eligible patients |
Important: The Rinvoq Complete Savings Card is not valid for Medicare, Medicaid, TRICARE, or other government-funded insurance. Patients enrolled in copay maximizer or optimizer programs may have reduced annual benefit amounts.
Humira / adalimumab biosimilar programs
| Program | Eligibility | Benefit |
|---|---|---|
| Humira Complete (brand) | Commercially insured | Copay assistance available; however, brand is effectively non-formulary on all three major PBMs in 2026 |
| Biosimilar manufacturer programs | Varies by manufacturer | Most biosimilar manufacturers offer copay assistance cards for commercially insured patients |
| Patient assistance (various) | Uninsured or underinsured | Available through individual biosimilar manufacturers and through AbbVie for brand Humira |
The practical reality is that brand Humira's patient support infrastructure is increasingly irrelevant because the product is excluded from major formularies. Patients who need adalimumab will be dispensed a biosimilar, and the specific biosimilar depends on their PBM's preferred product list.
For Rinvoq, the savings card and bridge program are critical access tools. Because Rinvoq requires PA with TNF blocker failure documentation, initial denials are common. The Rinvoq Bridge Program can provide free medication during the appeals process.
What to monitor
- Payer treatment sequencing evolution: As low-cost adalimumab biosimilars dominate first-line TNF inhibitor use, payers are building formulary pathways that route patients through biosimilar adalimumab before Rinvoq. Monitor whether this creates barriers to Rinvoq access beyond the label requirement.
- Rinvoq label expansion: AbbVie submitted an FDA application for severe alopecia areata in April 2026. If approved, this would be Rinvoq's tenth indication and could create new coverage dynamics in dermatology.
- JAK inhibitor safety data differentiation: Monitor whether long-term safety data supports any FDA labeling changes that distinguish Rinvoq from less selective JAK inhibitors. Any change to the boxed warning could significantly alter access.
- Biosimilar adalimumab pricing dynamics: Monitor whether biosimilar prices continue to drop, which would widen the cost gap with Rinvoq and strengthen payer preference for the adalimumab-first pathway.
- Rinvoq IRA negotiation eligibility: Monitor whether Rinvoq is selected for future Medicare Drug Price Negotiation rounds, which could reduce Part D costs and shift the cost comparison.
- Humira biosimilar market share shift: Brand Humira's >98% prescription share after biosimilar entry was rebate-driven. Monitor how quickly patients transition to biosimilars following the 2026 formulary exclusions.
- New oral small molecules: Monitor next-generation oral therapies that could compete with Rinvoq's oral advantage or with adalimumab biosimilars on cost.
Sources
- FDA, Rinvoq prescribing information (revised 2025): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211675s025lbl.pdf
- AbbVie, SELECT-SWITCH Phase 3b/4 results (October 2025): https://news.abbvie.com/2025-10-20-RINVOQ-R-upadacitinib-Demonstrated-Superiority-Versus-HUMIRA-R-adalimumab-for-Primary-Endpoint-in-a-Head-to-Head-Study-in-Rheumatoid-Arthritis-Patients-Who-Have-Failed-First-TNF-Inhibitor
- AbbVie, Rinvoq HCP coverage and access: https://www.rinvoqhcp.com/rheumatology/access
- FDA, JAK inhibitor safety communication: https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk
- Express Scripts, 2026 National Preferred Formulary: https://www.express-scripts.com/pdf/formulary/NPE1702_204612.pdf
- Drug Channels, 2026 formulary exclusions analysis: https://www.drugchannels.net/2026/01/the-big-three-pbms-2026-formulary.html
- PMC, Formulary coverage of adalimumab products: https://pmc.ncbi.nlm.nih.gov/articles/PMC11157442/
- Cencora, Humira biosimilar landscape overview: https://www.cencora.com/resources/therapeutic-expertise/humira-biosimilar-landscape-overview
- UnitedHealthcare, Rinvoq PA criteria: https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Med-Nec-Rinvoq-Rinvoq_LQ.pdf
- Cigna, Rinvoq PA policy: https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0682_coverage_position_criteria_inflammatory_conditions_rinvoq.pdf
- FDA, Biosimilar product information: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
